2015 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
11/30/15Three-Year Follow-Up Data From Lombard Medical Aorfix(TM) PYTHAGORAS Pivotal Trial Presented at 42nd Annual VEITHsymposium(TM)
Longer-Term Positive Outcomes in Abdominal Aortic Aneurysm Patients With Standard and Challenging Anatomies Reinforce the Broad Clinical Value of Aorfix IRVINE, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), presented efficacy and safety data from the three-year follow up of the U.S. PYTHAGORAS pre-marketing approval (PMA) trial of Aorfix™, the first and ... 
Printer Friendly Version
11/18/15Lombard Medical Announces Scientific Presentations on Aorfix(TM) and Altura(TM) Endovascular Stent Grafts at the 42nd Annual VEITHsymposium(TM)
Debut of Data on New IntelliFlex(TM) Delivery System and Early Clinical Experience With Altura IRVINE, Calif., Nov. 18, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that both of its endovascular stent grafts for AAA repair, Aorfix™ and Altura™, will be featured in scientific presentations at the 42nd annual VEITHsymposium™. Aorfix is the first and only e... 
Printer Friendly Version
11/12/15Lombard Medical Announces Positive Results of First-in-Man Clinical Case Using New Low Profile IntelliFlex(TM) LP Delivery System to Deploy Aorfix(TM) Endovascular Stent Graft
Design Enhances Control and Precision During Placement and Reduces Potential for Vessel Trauma IRVINE, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced the successful outcome of the first-in-man clinical EVAR case using its new low profile IntelliFlex™ LP Delivery System to deploy its endovascular stent graft, Aorfix™. The case was perfo... 
Printer Friendly Version
11/10/15Lombard Medical to Host VEITHsymposium(TM) Investor/Analyst Technology Workshop; Present at Upcoming Investor Conferences
IRVINE, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that management will host a technology workshop for investors and analysts at its VEITH Innovation Center at the New York Hilton-Midtown on November 17, 2015, from 3:00 p.m. and 5:00 p.m. ET. In addition, management is scheduled to attend the following upcoming investor conferences ... 
Printer Friendly Version
11/04/15Lombard Medical Reports 2015 Third Quarter, Nine-Month Results
Year-to-Date Aorfix Revenue Up 43 Percent Year-over-Year; Market Share in Japan Exceeds Five Percent in First Year of Sales IRVINE, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today reported financial results and provided an operational update for the third quarter and nine months ended September 30, 2015. Q3 and Recent Operational Highlights ... 
Printer Friendly Version
10/21/15Lombard Medical Announces 2015 Third Quarter and Nine-Month Financial Results Release and Conference Call Date
IRVINE, Calif., Oct. 21, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that it will release its 2015 third quarter and nine-month financial results after the market closes on Wednesday, November 4, 2015. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Wednesday, November 4, 2... 
Printer Friendly Version
09/09/15Peer Reviewed Article Highlights Performance of the Lombard Medical Aorfix(TM) Endovascular Stent Graft in Treating Challenging Neck Anatomy
Outcomes Similar to EVAR Trials With Less Challenging Anatomy IRVINE, Calif., Sept. 9, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), announced today that a new peer reviewed article e-published in August 2015 in the Journal of Vascular Surgery highlights the clinical benefits of treating patients with the Aorfix™ endovascular stent graft. The article, titled "Perform... 
Printer Friendly Version
09/08/15Lombard Medical Names David Milne to Board of Directors
IRVINE, Calif., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Lombard Medical Inc. (NASDAQ:EVAR), a medical device company focused on endovascular aortic repair of abdominal aortic aneurysms, today announced that medical device executive and investor David Milne has joined its Board of Directors, effective immediately. Mr. Milne, 53, serves as a managing partner of Boston-based venture capital firm SV Life Sciences. He has more than 30 years of operating, business development and venture capital experie... 
Printer Friendly Version
09/01/15400th Lombard Medical Aorfix(TM) Endovascular Stent Graft Procedure Completed One Year Following Japanese Approval and Launch
Lombard Estimates 5% Market Share Achieved IRVINE, Calif., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that within a year of the Aorfix™ regulatory approval in Japan, physicians have completed approximately 400 cases – or an estimated 5 percent of all AAA cases in Japan. Aorfix received approval from the Japanese Ministry of Health, Labour and We... 
Printer Friendly Version
07/30/15Lombard Medical Acquires Endovascular Stent Graft Developer Altura Medical
Acquisition Expands Lombard Product Portfolio with Simple, Safe and Efficient Ultra-Low Profile Endovascular Stent Graft CE Mark in Place – European Launch Scheduled for January IRVINE, Calif., July 30, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced the acquisition of Silicon Valley-based Altura Medical, a privately-held, venture-backed company that... 
Printer Friendly Version
07/27/15Lombard Medical Reports 2015 Second Quarter, Six-Month Results
Revenue Up 107 Percent Year-Over-Year; U.S. Sales Increase 123 Percent IRVINE, Calif., July 27, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today reported financial results and provided an operational update for the second quarter and six-months ended June 30, 2015. Q2 and Recent Operational Highlights Total 2015 second quarter Aorfix™ revenue grew 107 perc... 
Printer Friendly Version
07/20/15Lombard Medical Announces 2015 Second Quarter and Six-Month Financial Results Release and Conference Call Date
IRVINE, Calif., July 20, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that it will release its 2015 second quarter and six-month financial results after the market closes on Monday, July 27, 2015. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Monday, July 27, 2015, to disc... 
Printer Friendly Version
06/30/15First Clinical Cases Performed Using Lombard Medical's Aorfix(TM) Plus Endovascular Stent Graft
Increased Diameter May Allow 10 Percent Increase in Aorfix-Treatable AAA Cases IRVINE, Calif., June 30, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), announced today that the first clinical cases using its new Aorfix™ Plus endovascular stent graft have been successfully completed. The new addition to the Aorfix endovascular stent graft portfolio was recently approved... 
Printer Friendly Version
06/17/15Lombard Medical Set to Join Russell Microcap Index
IRVINE, Calif., June 17, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), announced today that it is set to join the Russell Microcap Index at the conclusion of the Russell indexes annual reconstitution on June 26, according to a preliminary list of additions posted June 12 at www.russell.com. Membership in the Russell Microcap Index, which remains in place for one year,... 
Printer Friendly Version
06/04/15Lombard Medical, Inc. (EVAR) to Present at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on June 10
NEW YORK, June 4, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (Nasdaq:EVAR), a CA-based medical device company, will be presenting at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on Wednesday, June 10. The event is a gathering of the brightest emerging growth small-cap and pre-IPO companies to present and network with an exclusive group of top-level institutional investors. Lombard Medical, Inc.: Simon Hubbert, CEO Time: 10:40 – 11:00 am (ET) Equi... 
Printer Friendly Version
06/02/15Lombard Medical Enters Group Purchasing Agreement With Novation to Offer Aorfix(TM) Endovascular Stent Graft to More Than 100,000 Healthcare Institutions in the U.S.
Three-year Contract Expands Access of Aorfix to Prestigious Academic Hospitals IRVINE, Calif., June 2, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today signed a three-year group purchasing agreement with Novation to offer its Aorfix™ Endovascular Stent Graft to the more than 100,000 members and affiliates that Novation serves. Aorfix is the first and only endovascular... 
Printer Friendly Version
05/26/15Lombard Medical to Present at the Jefferies Global Healthcare Conference
IRVINE, Calif., May 26, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that CEO Simon Hubbert is scheduled to present at the Jefferies 2015 Global Healthcare Conference on Tuesday, June 2, 2015, at 4:30 pm ET in New York City. A live audio webcast of the presentation will be available on the Events and Presentations page of the Investors section of Lombar... 
Printer Friendly Version
05/19/15First Commercial Cases with Lombard Medical's AorFlex(TM) Delivery System for Endovascular Aneurysm Repair Performed in Japan
AorFlex Delivery System Launched in Second Largest Standalone Endovascular Aneurysm Repair Market Through Exclusive Distribution Partner IRVINE, Calif., May 19, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAA), today announced that the first procedures were successfully performed in Japan using the Company's unique Aorfix™ Endovascular Stent Graft with the new AorFlex™ Delive... 
Printer Friendly Version
05/11/15Lombard Medical Reports 2015 First Quarter Results
Revenue Up 66 Percent Year-Over-Year; U.S. Sales Increase 125 Percent IRVINE, Calif., May 11, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today reported financial results for the first quarter ended March 31, 2015 and an operational update. Q1 and Recent Operational Highlights Total 2015 first quarter Aorfix revenue grew 66 percent1 to $3.4 million compared... 
Printer Friendly Version
04/30/15Lombard Medical to Present at Deutsche Bank Health Care Conference
IRVINE, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that CEO Simon Hubbert is scheduled to present at the Deutsche Bank Health Care Conference on Thursday, May 7, 2015, at 1:30 pm ET in Boston. A live audio webcast of the presentation will be available on the Events and Presentations page of the Investors section of Lombard Medical's ... 
Printer Friendly Version
04/28/15Lombard Medical Closes $26 Million Debt Facility With Oxford Finance
IRVINE, Calif., April 28, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), announced that it has entered into a $26 million secured term loan facility with Oxford Finance LLC. Lombard Medical received $11 million in proceeds from the loan at closing on April 24, 2015. The Company has the option of drawing another $10 million after achieving a specific near-term revenue miles... 
Printer Friendly Version
04/27/15Lombard Medical Announces Live Case Presentation on Aorfix(TM) Endovascular Stent Graft at Charing Cross International Symposium
IRVINE, Calif. and LONDON, April 27, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that Aorfix™, an endovascular stent graft for AAA repair, will be featured in a new Edited Live Case session at the 37th Charing Cross (CX) International Symposium. Aorfix is the first and only endovascular stent graft with global approvals for the treatment of patients with... 
Printer Friendly Version
04/22/15Lombard Medical Enrolls First Patient in ARCHYTAS Global Clinical Registry
IRVINE, Calif., April 22, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced the enrollment and treatment of the first patient in the ARCHYTAS global registry. An 89-year-old male with a 64mm aneurysm and challenging 75 degree aortic neck angulation was treated with Lombard Medical's Aorfix™ Endovascular Stent Graft in Girona, Spain. "Aorfix was deployed ea... 
Printer Friendly Version
04/21/15Lombard Medical Announces 2015 First Quarter Financial Results Release and Conference Call Date
IRVINE, Calif., April 21, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that it will release its 2015 first quarter financial results after the market closes on Monday, May 11, 2015. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Monday, May 11, 2015, to discuss the financia... 
Printer Friendly Version
04/15/15Lombard Medical Initiates Post-Marketing Surveillance Program for Aorfix(TM) Endovascular Stent Graft
IRVINE, Calif., April 15, 2015 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced the successful enrollment of the first patients in its post-marketing surveillance program for Aorfix™. Aorfix is the first and only endovascular stent graft with global approvals for the treatment of patients with aortic neck angulations up to 90 degrees, often a feature of complicate... 
Printer Friendly Version
03/13/15Lombard Medical Receives Regulatory Approval in Japan for AorFlex™ Endovascular Stent
... 
Printer Friendly Version
03/02/15Lombard Medical to Present at Upcoming Investor Conferences.
... 
Printer Friendly Version
02/27/15Lombard Medical Reports 2014 Fourth Quarter, Full Year Financial Results
... 
Printer Friendly Version
02/17/152014 Fourth Quarter and Year-End Financial Results Release and Conference Call Date
... 
Printer Friendly Version
02/11/15Michael H. Carrel has been appointed to the Company’s Board of Directors
... 
Printer Friendly Version
02/05/15FDA Approval For Aorfix™Plus Endovascular Stent Graft Expanding Its Addressable Market
... 
Printer Friendly Version
01/29/15Lombard Medical Announces Successful Completion of Live EVAR Case with Aorfix™ Endovascular Stent Graft at 11th Annual Leipzig Interventional Course (LINC) 2015
... 
Printer Friendly Version
01/28/15Lombard Medical Initiates ARCHYTAS Global Clinical Registry
... 
Printer Friendly Version
01/08/15Lombard Medical Announces Preliminary 2014 Fourth Quarter and Full Year Revenues
... 
Printer Friendly Version